Rosetta Genomics advances new diagnostic tests into development

The new development programs include response prediction to ovarian cancer treatment, predicting risk of gastric cancer recurrence, and differentiation of small cell from non-small cell lung cancer. The company expects to develop and market the new tests through its own clinical laboratory improvement amendments CLIA-certified laboratory, for which the company recently signed a binding acquisition term sheet.

Leveraging unique microRNA biomarkers identified using Rosetta Genomics’s proprietary microRNA extraction and quantification methods, the new programs are expected to be clinically available during 2009-2010.

Ronen Tamir, executive vice president of marketing and communication at Rosetta, said: “Our rich product pipeline, combined with the upcoming acquisition of a commercial CLIA-certified laboratory, will position us to participate in such a growth trend in the molecular diagnostics industry.”